Inotiv Inc
NOTV
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
1660.9% downsideOvervalued by 1660.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.98 Million |
|---|---|
| Enterprise Value | $505.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.11 |
| Beta | 3.83 |
| Outstanding Shares | 34,653,000 |
Return
| Return on Equity | -112.81% |
|---|---|
| Return on Assets | -12.38% |
| Return on Invested Capital | -23.81% |
Valuation & Multiples
| P/E Ratio | -0.11 |
|---|---|
| PEG | -0.1 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | 1 |
| Enterprise Value to EBIT | -13.08 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 1.01 |
| Debt to Equity | 6.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 90.91% |
|---|---|
| Total Calls | 36,100▲ 228.18% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.87%▼ 8.16% |
|---|---|
| Total Invested | $1.30M▼ 69.47% |
| Investors Holding | 51▼ 7.00% |
ESG Score
No data
About Inotiv Inc
409 employees
CEO: Jacqueline Lemke Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development compa...
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending (including Medicare). Its decisions on corporate tax policy, R&D credits, and Medicare drug pricing directly affect the profitability, investment incentives, and market opportunities for Inotiv and its pharmaceutical clients.
This committee directly allocates discretionary federal spending. Its subcommittees determine the precise funding levels for agencies like the NIH and FDA, directly impacting the availability of research grants, regulatory capacity, and potential government contracts vital to Inotiv's clients and operations.
This committee directly regulates the FDA and NIH, which are central to drug approval processes and pharmaceutical research funding. Its decisions profoundly influence the speed, cost, and feasibility of bringing new drugs to market, directly impacting Inotiv's core business.